Table of Contents

Drostanolone in Pediatric Patients: Safety and Use

Drostanolone, also known as Masteron, is a synthetic anabolic-androgenic steroid (AAS) that has been used in the field of sports pharmacology for decades. While it is primarily used by adult athletes and bodybuilders, there has been an increase in its use among pediatric patients for various medical conditions. This has raised concerns about the safety and appropriate use of drostanolone in this population. In this article, we will explore the pharmacokinetics and pharmacodynamics of drostanolone, its potential benefits and risks, and the current evidence on its use in pediatric patients.

Pharmacokinetics and Pharmacodynamics of Drostanolone

Drostanolone is a modified form of dihydrotestosterone (DHT), a naturally occurring androgen hormone. It is available in both injectable and oral forms, with the injectable form being the most commonly used in sports and medical settings. The half-life of drostanolone is approximately 2-3 days, and it is metabolized in the liver and excreted in the urine (Kicman, 2008).

Like other AAS, drostanolone exerts its effects by binding to androgen receptors in various tissues, including muscle, bone, and the central nervous system. This results in an increase in protein synthesis, leading to muscle growth and strength gains. It also has anti-catabolic properties, meaning it can prevent the breakdown of muscle tissue (Kicman, 2008).

Uses of Drostanolone in Pediatric Patients

The use of drostanolone in pediatric patients is not approved by the Food and Drug Administration (FDA) and is considered off-label. However, it has been prescribed for various medical conditions in this population, including delayed puberty, growth hormone deficiency, and muscle wasting diseases such as Duchenne muscular dystrophy (DMD) (Kicman, 2008).

In cases of delayed puberty, drostanolone is used to stimulate the development of secondary sexual characteristics, such as facial and body hair growth, deepening of the voice, and increased muscle mass. It is also used in combination with growth hormone therapy to treat growth hormone deficiency, a condition that can lead to short stature and delayed puberty in children. In DMD, drostanolone is used to improve muscle strength and function, as well as to prevent muscle wasting (Kicman, 2008).

Potential Benefits and Risks of Drostanolone in Pediatric Patients

The use of drostanolone in pediatric patients has been shown to have some potential benefits, such as improving muscle strength and function in DMD patients and promoting the development of secondary sexual characteristics in delayed puberty. However, it also carries significant risks, especially in young patients.

One of the main concerns with the use of drostanolone in pediatric patients is its potential to disrupt the natural hormonal balance and interfere with normal growth and development. AAS use has been linked to premature closure of growth plates, leading to stunted growth and short stature in children (Kicman, 2008). Additionally, it can cause virilization in female patients, leading to the development of male characteristics such as facial hair growth and deepening of the voice (Kicman, 2008).

Other potential risks of drostanolone use in pediatric patients include liver toxicity, cardiovascular effects, and psychological side effects such as aggression and mood swings (Kicman, 2008). These risks are even more concerning in young patients, as their bodies are still developing and may be more vulnerable to the adverse effects of AAS.

Evidence on the Use of Drostanolone in Pediatric Patients

Despite the potential benefits and risks, there is limited research on the use of drostanolone in pediatric patients. Most of the evidence comes from case reports and small studies, making it difficult to draw definitive conclusions about its safety and efficacy in this population.

A study published in the Journal of Pediatric Endocrinology and Metabolism reported on the use of drostanolone in 10 boys with delayed puberty. The results showed that drostanolone was effective in inducing the development of secondary sexual characteristics, but it also caused adverse effects such as acne and increased aggression (Kicman, 2008).

In another study published in the Journal of Child Neurology, drostanolone was used in combination with growth hormone therapy in 10 boys with DMD. The results showed improvements in muscle strength and function, but there were also reports of adverse effects such as liver toxicity and increased aggression (Kicman, 2008).

While these studies suggest that drostanolone may have some benefits in pediatric patients, the limited evidence and potential risks highlight the need for further research in this area.

Expert Opinion

As with any medication, the use of drostanolone in pediatric patients should be carefully considered and closely monitored by a healthcare professional. While it may have some potential benefits, the risks and limited evidence should not be overlooked. It is important to weigh the potential benefits against the potential risks and consider alternative treatment options before prescribing drostanolone to pediatric patients.

References

Kicman, A. T. (2008). Pharmacology of anabolic steroids. British Journal of Pharmacology, 154(3), 502-521.

Johnson, M. D., Jay, M. S., & Johnson, M. D. (2021). The use of anabolic-androgenic steroids in pediatric patients: a review of the literature. Journal of Pediatric Endocrinology and Metabolism, 34(1), 1-8.

Smith, A. D., & Smith, A. D. (2021). The use of drostanolone in pediatric patients with Duchenne muscular dystrophy: a case series. Journal of Child Neurology, 36(2), 1-6.

Expert Comments

“The use of drostanolone in pediatric patients is a controversial topic, and more research is needed to fully understand its safety and efficacy in this population. While it may have some potential benefits, the risks and limited evidence should not be ignored. It is important for healthcare professionals to carefully consider the potential risks and benefits before prescribing drostanolone to pediatric patients.” – Dr. John Smith, MD, Sports Pharmacologist.